**Specifications Table**TableSubject areaPharmacologyMore specific subject areaNeuropsychopharmacologyType of dataTablesHow data was acquiredExperimental study in male wistar rats, as described belowData formatProcessed tabulated dataExperimental factorsPlasma samples were collected for bioanalysis of risperidone, paliperidone, and remoxipride using an on-line solid phase extraction with liquid chromatography -- tandem mass spectrometry method. Serum prolactin levels were measured using an enzyme linked immunosorbent assay technique.Experimental featuresAll animal procedures were performed at Leiden University, in accordance with Dutch laws governing animal experimentation. Male Wistar rats, received single intravenous doses of risperidone (2 mg/kg, *n*=16) or paliperidone (0.5 mg/kg, *n*=21). Plasma drug concentrations as well as plasma prolactin levels were measured at pre-dose and at serial intervals post-dose. In another study, remoxipride was administered to rats either as a single intravenous dose of 4, 8 or 16 mg/kg (*n*=10) remoxipride or two doses of 3.8 mg/kg at varying dosing intervals. Blood samples were serially collected.\
Plasma concentrations of the drugs as well as prolactin were assayed using validated analytical methods.Data source locationDepartment of Pharmacology, Leiden Academic center for Drug Research, Leiden.Data accessibilityThe data is within this article.

**Value of the data**

Data can be used•To compare experimental findings in literature with our model-based approach.•As prior information, especially when the available data is scarce.•For exploratory modeling.•For translation from rat to humans.

1. Data {#s0005}
=======

The information is presented in 4 tables. [Table 1](#t0005){ref-type="table"} presents the in vitro inhibition constant (*KI*) values in rat and humans and physicochemical characteristics of the antipsychotics risperidone, paliperidone and remoxipride. [Table 2](#t0010){ref-type="table"} presents the pharmacokinetic--pharmacodynamic model parameters used to perform exploratory model simulations of the precursor pool model, as referred to in Section 3.2, Fig. 5 of Taneja et al. [@bib1]. [Table 3](#t0015){ref-type="table"} presents the model parameters assuming equal or different potency of risperidone and paliperidone. [Table 4](#t0020){ref-type="table"} presents the model parameters obtained with different parameterizations, assuming either unbound drug concentration or dopamine D~2~ receptor occupancy as the driving force for drug effect.

2. Experimental design, materials and methods {#s0010}
=============================================

Details of the experimental procedures have been described previously [@bib1], [@bib5], [@bib6].
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###### 

Overview of literature *KI* values and physicochemical characteristics of risperidone, paliperidone and remoxipride.

Table 1

                                                                   **Risperidone**   **Paliperidone**   **Remoxipride**
  ---------------------------------------------------------------- ----------------- ------------------ -----------------
  ***KI*****values** (nM)                                                                               
  Rat[⁎](#tbl1fnStar){ref-type="table-fn"}                         2.55              2.74               370.66
  Human[⁎](#tbl1fnStar){ref-type="table-fn"}                       2.18              2.08               165.75
  Human[⁎⁎](#tbl1fnStarStar){ref-type="table-fn"}                  4.9 / 6           NA                 243 / 125
  **Physicochemical characteristics**                                                                   
  Protein binding % (rat)[⁎](#tbl1fnStar){ref-type="table-fn"}     88.2              74.7               20-30
  Protein binding % (human)[⁎](#tbl1fnStar){ref-type="table-fn"}   90                77.4               80
  Molecular weight (g/mol)                                         410.48            426.48             371.26

Data on file.

Data from Richtand et al. [@bib2]. Values depicted for D~2~ and D~2~ long receptor in vitro experimental *KI*.

###### 

Model parameters used for the simulations in exploratory model analysis. Pharmacokinetic and pharmacodynamic parameters obtained from Kozielska et al. [@bib3] and Stevens et al. [@bib4], respectively.

Table 2.

  Parameter                       Estimate
  ------------------------------- -------------------------------------------
  *CL* (l·h^-1^)                  1.62
  *V1* (l)                        1.29
  *Q* (l·h^-1^)                   0.0882
  *V2* (l)                        0.169
  *F*                             1
  *Ka* (h^-1^)                    2.84
  *C*~*prl,0*~ (ng·ml^-1^)        6.2
  *R*~*form*~ (ng·ml^-1^·h^-1^)   35.3[⁎](#tbl2fnStar){ref-type="table-fn"}
  *K*~*base*~ (h^-1^)             0.57
  *K*~*out*~ (h^-1^)              5.7
  *E*~*max*~                      25
  *EC*~*50*~ (ng·ml^-1^)          0.08
  *γ*                             1
  *E*~*max_pf*~                   3.5
  *EC*~*50_pf*~ (ng·ml^-1^)       12.4

*CL* = clearance from the central compartment, *V1* = volume of the central compartment, *Q* = intercompartmental clearance, *V2* = volume of the peripheral compartment, *F* = bioavailability, *Ka* = absorption constant, *C*~*prl,0*~ = plasma concentration of prolactin in the absence of antipsychotic drug, *R*~*form*~ = zero-order rate constant for prolactin synthesis, *K*~*base*~ = first-order rate constant of prolactin release from the pool, *K*~*out*~ = first-order rate constant of elimination of prolactin from plasma, *E*~*max*~ = maximum increase in the prolactin release from the pool, *E*C~*50*~ = drug concentration at half-maximal effect, *γ* = slope parameter, *E*~*max_pf*~ = maximum prolactin feedback, *EC*~*50_pf*~ = plasma prolactin concentration at half-maximal effect.

*R*~*form*~ is calculated as the product of *C*~*prl,0*~ . *K*~*out*~ (equation (5) of Taneja et al. [@bib1]).

###### 

Parameter comparison (relative standard error in %) of the pool model with different *ECu*~*50*~ for risperidone and paliperidone vs. single *ECu*~*50*~ and the interaction model with different *KI* for risperidone and paliperidone vs single *KI*.

Table 3

                                  Estimates    
  ------------------------------- ------------ ------------
  **Pool Model**                  52.1 (12)    48.7 (12)
  *R*~*form*~ (ng.ml^-1^×h^-1^)                
  *K*~*base*~ (h^-1^)             0.251 (12)   0.250 (12)
  *K*~*out*~ (h^-1^)              6.96 (14)    6.57 (12)
  *E*~*max*~                      3.5 FIXED    3.5 FIXED
  *ECu*~*50*~ paliperidone (nM)   38.2 (52)    35.1 (51)
  *ECu*~*50*~ risperidone (nM)    39.6 (142)   
  *ECu*~*50*~ remoxipride (nM)    95.2 (41)    94.8 (31)
  *γ*                             1 FIXED      1 FIXED
  IIV *R*~*form*~ (%)             40 (18)      40 (18)
  Residual error (%)              50 (7)       50 (7)
  Minimization                    ++           ++
  Covariance                      ++           ++
  Objective Function Value        3454.764     3455.775
  **Interaction Model**           23.8 (6)     23.8 (6)
  *K*~*in,0*~ (ng.ml^-1^×h^-1^)                
  *K*~*out*~ (h^-1^)              3.35 (10)    3.34 (9)
  *K*~*DA*~ (h^-1^)               5.12 (19)    5.51 (21)
  *DAs*~*0*~ (dimensionless)      1000 FIXED   1000 FIXED
  *KI* paliperidone (nM)          34.1 (11)    35.7 (12)
  *KI* risperidone (nM)           47.7 (20)    
  *KI* remoxipride (nM)           370 (11)     360 (11)
  *γ*                             1 FIXED      1 FIXED
  IIV *K*~*in,0*~ (%)             40 (22)      40 (22)
  Residual error (%)              56 (12)      56 (12)
  Minimization                    ++           ++
  Covariance                      ++           ++
  Objective Function Value        3727.802     3726.086

*R*~*form*~ = zero-order rate constant for prolactin synthesis, *K~base~* = first-order rate constant of prolactin release from the pool, *K*~*out*~ = first-order rate constant of elimination of prolactin from plasma, *E*~*max*~ = maximum increase in the prolactin release from the pool, *EC*~*u50*~ = unbound drug concentration at half-maximal effect, *γ* = slope parameter, IIV = inter-individual variability, *K*~*in,0*~ = basal prolactin release rate, *K*~*DA*~ = first-order turnover constant for hypothetical dopamine, *DAs~0~* = hypothetical scaled dopamine concentration at baseline, *KI* = drug potency parameter.

###### 

Pool model: Comparison of parameter estimates with parameterization of drug effects as *ECu*~*50*~ as compared to *RO*~*50*~ (relative standard error in %).

Table 4

  **Parameter**                               **Estimates using*****ECu***~***50***~   **Estimates using*****RO***~***50***~
  ------------------------------------------- ---------------------------------------- ---------------------------------------
  *R*~*form*~ (ng.ml^-1^×h^-1^)               45.7 (10)                                49.8 (10)
  *K*~*base*~ (h^-1^)                         0.25 (10)                                0.226 (11)
  *K*~*out*~ (h^-1^)                          6.06 (12)                                6.96 (13)
  *E*~*max*~                                  3.5 FIXED                                3.5 FIXED
  *ECu*~*50*~ risperidone/paliperidone (nM)   35.1 (51)                                [⁎](#tbl4fnStar){ref-type="table-fn"}
  *ECu*~*50*~ remoxipride (nM)                94.8 (31)                                [⁎](#tbl4fnStar){ref-type="table-fn"}
  *RO*~*50*~ (%)                              NA                                       28.7 (27)
  *γ*                                         1 FIXED                                  1 FIXED
  IIV *K*~*out*~ (%)                          42.1 (18)                                42.3 (18)
  Residual error - proportional (%)           47.2 (4)                                 37.4 (8)
  Residual error - additive (ng·ml^-1^)       NE                                       2.68 (29)
  Minimization                                ++                                       ++
  Covariance step                             ++                                       ++
  Objective Function Value                    3434.44                                  3430.56

*R*~*form*~ = zero-order rate constant for prolactin synthesis, *K~base~* = first-order rate constant of prolactin release from the pool, *K~out~* = first-order rate constant of elimination of prolactin from plasma, *E*~*max*~ = maximum increase in the prolactin release from the pool, *EC*~*u50*~ = unbound drug concentration at half-maximal effect, *RO*~*50*~ = receptor occupancy at half-maximal effect, *γ* = slope parameter, IIV = inter-individual variability.

NA = not applicable.

NE = not estimated.

*KI* risperidone/paliperidone = 2.55 nM, *KI* remoxipride = 370.66 nM (fixed to in vitro experimental values).

[^1]: Present address: Pharmacometrics and Biometrics, Kinesis Pharma BV, Breda, The Netherlands.
